TELA Bio (NASDAQ:TELA) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

TELA Bio (NASDAQ:TELA) announced its earnings results on Thursday. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01, Zacks reports. TELA Bio had a negative net margin of 60.49% and a negative return on equity of 556.18%. TELA Bio updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

TELA Bio Stock Performance

NASDAQ TELA traded down $0.02 during trading hours on Thursday, hitting $2.34. 121,246 shares of the stock were exchanged, compared to its average volume of 199,376. The company has a market cap of $92.17 million, a price-to-earnings ratio of -1.38 and a beta of 1.10. TELA Bio has a 12-month low of $1.75 and a 12-month high of $6.50. The stock has a 50-day moving average of $2.60 and a 200 day moving average of $2.71. The company has a quick ratio of 1.81, a current ratio of 2.62 and a debt-to-equity ratio of 14.22.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.